Cerus Corporation

NASDAQ:CERS

Medical - Devices

Healthcare
$1.94 +2.92%

+$0.08 today

Market cap
$391.79M
Beta
1.77
P/E (TTM)
-53.8
EPS (TTM)
-$0.05
52W Low $1.15High $3.15

Volume 6.09M

Average 2.33M

CERS Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Cerus CorporationNASDAQ: CERS

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables declines year over year

Q1 FY2026 accounts payables of $4.14M fell 17.8% year over year, ahead of the -50.2% change in trailing-twelve-month accounts payables. Sequentially, it rose 75.2% from the prior quarter.

Context

  • Accounts payables amounted to 2.8% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -17.8% holds above the trailing-twelve-month pace of -50.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.14M+75.2% QoQ
Last fiscal yearDec 2025
$5.73M+487.6% YoY
LTMMar 2026
$4.83M-50.2% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.8%——
1 year+487.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
5.73M USD
Year-over-year change
+487.6%
4-year CAGR
-17.2%

Accounts Payables vs competitors

How CERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -50.2% is the 3rd highest of 4, against a peer median of +161.8%.
  • Accounts payables amounts to 2.2% of revenue for CERS, versus a peer median of 0.7%.
CERS Competitors
Accounts Payables for CERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRFSGrifols, S.A.LTM Jun 2026€48.79M EUR+178.3%+4.0%0.7%
HAEHaemonetics CorporationLTM Jun 2026$18.71M USD+161.8%—1.4%
CERSCerus CorporationLTM Mar 2026$4.83M USD-50.2%—2.2%
ADMAADMA Biologics, Inc.LTM Jun 2026$1.77M USD-88.2%+42.8%0.3%
Peer median (excluding CERS) —+161.8%+23.4%0.7%

Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(54.38M)(42.83M)(37.49M)(20.96M)(15.63M)
Depreciation & Amortization3.15M2.98M2.6M1.86M1.86M
Deferred Income Tax462K0000
Stock-Based Compensation23.57M24.46M20.27M22.87M22.87M
Change in Working Capital(9.4M)(16.05M)(32.04M)5.23M(6.83M)
Accounts Receivables(4.22M)(9.2M)(1.1M)5.5M(396K)
Inventory(19.61M)(1.77M)(14.95M)7.03M(14.68M)
Accounts Payables12.2M(4.91M)(7.34M)(1.48M)5.73M
Other Working Capital2.22M(179K)(8.65M)(5.83M)2.52M
Other Non-Cash Items2.67M5.82M3.49M2.37M9.09M
Operating Cash Flow(33.92M)(25.62M)(43.17M)11.36M11.36M
Capital Expenditures(910K)(2M)(4.6M)(2.84M)(2.84M)
Acquisitions (Net)910K(10.46M)000
Purchases of Investments(52.07M)(29.64M)(2.49M)(42.98M)(42.98M)
Sales of Investments65.66M40.1M15.71M37.68M37.68M
Other Investing Activities(910K)10.46M000
Investing Cash Flow12.69M8.46M8.62M(8.13M)(8.13M)
Debt Repayment21.18M212K9.92M4.3M(329K)
Common Stock Issued2.74M000560K
Common Stock Repurchased0(104K)(175K)00
Dividends Paid00000
Other Financing Activities10.37M4.08M925K667K4.73M
Financing Cash Flow34.29M4.19M10.67M4.96M4.96M
Effect of Forex Changes(919K)(727K)(128K)(191K)(191K)
Net Change in Cash12.14M(13.69M)(24M)8M8M
Free Cash Flow(34.83M)(27.62M)(47.77M)8.52M8.52M

Cerus Corporation

NASDAQ:CERS

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.